<p>The MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, What are the unmet needs in the management of myelofibrosis-related anemia? </p><br><p>In this interview, Kiladjian explores the impact and multifactorial causes of myelofibrosis-related anemia, with particular attention to the on-target effects of JAK inhibition. He reviews currently approved JAK inhibitors, emphasizing the anemia benefits seen with momelotinib and pacritinib. Kiladjian also underscores that JAK inhibitors alone do not completely address myelofibrosis-related anemia, highlighting the potential of JAK inhibitor-based combination therapies to address this unmet need.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>